Focal HDR Brachytherapy Boost to Stereotactic Radiotherapy
Recruiting now Phase 2 NCT04100174
Run by Centre hospitalier de l'Université de Montréal (CHUM) · for All ages · Men
What this study is about
To determine if fBT+sRT is superior to standard care in terms of urinary toxicity by having fewer patients experience a minimal important decline (MID) in urinary irritation/obstructive QoL
Who can join (things the study team will check)
✅ You may be able to join if…
- Histological diagnosis of prostate cancer planned for curative-intent HDR brachytherapy boost to external beam radiotherapy to the prostate gland.
- ECOG 0-1
- Charlson Comorbidity Index ≤ 4
- Imaging visible disease encompassing < 50% of the prostate gland and consistent with biopsy findings. Exclusion - none
Where this trial is running
- Centre Hospitalier de l'Université de Montréal, Montreal, Quebec, Canada
- CHUQ, Québec, Quebec, Canada
Who to contact
Mom Phat · 514-890-8254 · mom.phat.chum@ssss.gouv.qc.ca
It's completely normal to call and ask questions before deciding anything. Mention the study ID: NCT04100174.
Verify everything on the official ClinicalTrials.gov record. Page updated July 2026.
Beacon is an information tool, not medical advice. Whether a trial is right for you is a decision for you, your doctor, and the study team. Trial details come from the official registry, ClinicalTrials.gov, and may change — always confirm with the study team. Beacon collects no data about you: this page has no cookies, no accounts, and no tracking.